Literature DB >> 17983451

Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.

J C Fallon1, S Patchett, C Gulmann, G M Murphy.   

Abstract

Tumour necrosis factor-alpha inhibitors including infliximab are often used to treat a number of recalcitrant medical conditions. These agents are increasingly associated with infections, particularly mycobacterial infections. We report sporotrichoid spread of Mycobacterium marinum in a 37-year-old woman with Crohn's disease, who had been receiving infliximab infusions for 2 years. An infection had spread up the right leg, after she had been swimming on holiday in the Canary Islands. M. marinum was cultured from the lesions and also identified by PCR on formalin-fixed tissue. To our knowledge, this is the first report of M. marinum occurring in a patient receiving infliximab.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983451     DOI: 10.1111/j.1365-2230.2007.02564.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

Review 1.  [Infections due to Mycobacterium marinum: a review].

Authors:  P Nenoff; B-M Klapper; P Mayser; U Paasch; W Handrick
Journal:  Hautarzt       Date:  2011-04       Impact factor: 0.751

Review 2.  Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Clin Rheumatol       Date:  2011-12-15       Impact factor: 2.980

3.  Mycobacterium marinum osteomyelitis of the first metatarsal.

Authors:  Ibon López Zabala; Daniel Poggio Cano; Rubén García-Elvira; Jordi Asunción Márquez
Journal:  Eur J Orthop Surg Traumatol       Date:  2011-11-26

4.  Atypical mycobacterial infection presenting as persistent skin lesion in a patient with ulcerative colitis.

Authors:  Giorgos Bamias; George L Daikos; Spyros I Siakavellas; Garyfallia Kaltsa; Stavroula Smilakou; Ioannis Katsogridakis; Irene Vafiadis-Zouboulis; Spiros D Ladas
Journal:  Case Rep Med       Date:  2011-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.